10-Q: Charles River Labs Q3 2025: Revenue Dips, Strategic Review Underway

Charles River Laboratories International, Inc. reported a slight revenue decrease for Q3 2025 and the nine months ended September 27, 2025, alongside a significant drop in net income for the nine-month period, as it navigates a cautious client spending environment and implements a comprehensive strategic review.

Summary

• Total revenue for the three months ended September 27, 2025, decreased by 0.5% to $1,004.9 million, compared to $1,009.8 million in the corresponding period of 2024.
• Total revenue for the nine months ended September 27, 2025, decreased by 0.9% to $3,021.2 million, compared to $3,047.4 million in the corresponding period of 2024.
• Operating income for the three months ended September 27, 2025, increased by 14.0% to $133.8 million, compared to $117.4 million in the corresponding period of 2024, driven by lower severance and unallocated corporate employee compensation costs.
• Operating income for the nine months ended September 27, 2025, decreased by 21.9% to $308.6 million, compared to $395.0 million in the corresponding period of 2024, primarily due to accelerated amortization, increased restructuring activities, and higher third-party legal and advisory costs.
• Net income attributable to common shareholders decreased to $54.4 million for the three months ended September 27, 2025, from $68.7 million in the prior year, and to $132.2 million for the nine months ended September 27, 2025, from $226.0 million in the prior year.
• Diluted earnings per common share decreased to $1.10 for the three months ended September 27, 2025, from $1.33 in the prior year, and to $2.65 for the nine months ended September 27, 2025, from $4.37 in the prior year.
• Cash flows from operations increased to $590.1 million for the nine months ended September 27, 2025, from $575.2 million in the prior year, primarily due to lower variable compensation payments and favorable timing of payments to suppliers.
• The effective tax rate increased to 36.3% for the three months and 31.1% for the nine months ended September 27, 2025, primarily due to increased U.S. taxation of foreign operations and new foreign tax legislation.
• The company is implementing restructuring actions, incurring charges of $17.3 million for the three months and $73.3 million for the nine months ended September 27, 2025, to optimize its global footprint and drive efficiency.
• A comprehensive strategic review by the Board of Directors was announced in November 2025, focusing on strengthening the scientific portfolio, divesting non-core assets (approximately 7% of estimated 2025 revenue), maximizing financial performance with incremental cost savings, and disciplined capital deployment.

Sentiment

Score: 3

Explanation: The company faces significant financial headwinds, including a substantial decline in nine-month net income and EPS, and a slight revenue decrease. While Q3 operating income improved due to cost-cutting, the overall nine-month operating performance is down. Ongoing legal challenges and a cautious market environment add uncertainty. The strategic review and focus on alternative methodologies are positive long-term initiatives, but current performance indicates a challenging period.

Positives

• Research Models and Services (RMS) segment revenue increased by 7.9% to $213.5 million in Q3 2025 and 2.4% to $639.8 million for the nine months, driven by large research model product revenue (notably from Noveprim) and small model product revenue in Europe and China.
• Q3 2025 operating income increased by 14.0% to $133.8 million, primarily due to lower severance costs and reduced unallocated corporate employee compensation and benefits related costs.
• Net cash provided by operating activities increased to $590.1 million for the nine months ended September 27, 2025, from $575.2 million in the prior year.
• The U.S. Department of Justice (DOJ) and U.S. Fish and Wildlife Service (USFWS) investigations into non-human primate (NHP) shipments were closed in Q3 2025, and the NHP shipments were cleared for legal entry into the United States.
• The strategic review is expected to generate approximately $225 million of cost savings on an annualized basis, with approximately $175 million impacting fiscal year 2025, and an additional $70 million annually in incremental net cost savings fully realized in 2026.
• Interest expense decreased by 16.1% to $25.4 million for the three months and 15.1% to $83.3 million for the nine months ended September 27, 2025, due to lower average debt balances.

Negatives

• Total revenue decreased by 0.5% in Q3 2025 and 0.9% for the nine months ended September 27, 2025, primarily due to declines in the Discovery and Safety Assessment (DSA) and Manufacturing segments.
• Net income attributable to common shareholders decreased significantly to $54.4 million in Q3 2025 (from $68.7 million) and $132.2 million for nine months 2025 (from $226.0 million).
• Diluted EPS decreased to $1.10 in Q3 2025 (from $1.33) and $2.65 for nine months 2025 (from $4.37).
• DSA segment revenue decreased by 2.3% in Q3 2025 and 2.0% for the nine months, due to lower volume driven by continued cautious client spending.
• Manufacturing segment revenue decreased by 3.1% in Q3 2025 and 0.8% for the nine months, primarily due to decreased demand for CDMO and Biologics Testing services.
• Nine-month operating income decreased by 21.9% to $308.6 million, primarily due to $71.0 million of accelerated amortization expense from the loss of key CDMO customers, increased restructuring activities (including higher asset impairments and site consolidation charges), and higher third-party legal and advisory costs.
• Other expense, net, was $22.6 million for Q3 2025 (compared to $2.6 million income in Q3 2024) and $34.7 million for nine months 2025 (compared to $6.2 million income in nine months 2024), driven by significant net losses and impairments on venture capital and strategic equity investments totaling $33.955 million for the nine months.
• The effective tax rate increased significantly to 36.3% for Q3 2025 (from 23.0%) and 31.1% for nine months 2025 (from 22.9%).
• DSA backlog declined slightly to $1.8 billion as of September 27, 2025, from $2.0 billion as of December 28, 2024.

Risks

• An ongoing U.S. Securities and Exchange Commission (SEC) inquiry related to the sourcing of non-human primates and related disclosures, with unpredictable timing, outcome, or potential fines, penalties, or liabilities.
• A putative securities class action lawsuit, which was partially reinstated by the U.S. Court of Appeals for the First Circuit, returning the case to the U.S. District Court for the District of Massachusetts, with an unpredictable final outcome and potential exposure.
• Two derivative lawsuits filed against members of the Board of Directors and certain current/former officers, asserting claims of breached fiduciary duties and insider-trading, currently stayed pending developments in the Securities Class Action.
• A cautious spending environment from global biopharmaceutical and biotechnology clients, leading to budget reassessments, reprioritization of drug pipelines, and management of cost structures, which could diminish demand for products and services.
• Potential reduction or delay in government funding of R&D, including policy changes by agencies like the U.S. National Institutes of Health (NIH) that could adversely affect client funding and demand.
• Changes in government regulation or practices relating to the pharmaceutical or biotechnology industries, such as relaxation of regulatory requirements or increased requirements that make services less competitive, could reduce demand for services.
• The U.S. Food and Drug Administration (FDA)'s plans to launch a pilot program to reduce animal testing in preclinical safety studies with scientifically validated cell-based and new approach methodologies (NAMs) could reduce demand for traditional animal models.
• Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition, including tariffs (e.g., between the U.S. and countries like Vietnam, Mauritius, and China), which may adversely impact operating margin and supply chain operations.
• Failure to successfully execute the business strategy or the Board of Directors' comprehensive strategic review and evaluation of business and growth prospects could negatively impact future results of operations and market capitalization.
• Inability to timely build infrastructure to satisfy capacity needs and support business growth due to factors such as insufficient capital, inflation, supply chain interruptions, increases in construction material costs, or labor shortages.
• Quarterly operating results may vary due to factors including changes in the global economy, product/service mix, regulatory changes, cyclical client buying patterns, financial performance of strategic and venture capital investments, and acquisition-related adjustments.
• The process of reviewing potential strategic alternatives is time-consuming and costly, may divert management's attention, disrupt business operations, cause concern to stakeholders, and result in increased volatility in the stock price, with no assurance of successful implementation or intended benefits.

Future Outlook

The company anticipates approximately $225 million in annualized cost savings from ongoing restructuring actions, with about $175 million expected to impact fiscal year 2025. An additional $70 million in incremental net cost savings annually is projected from strategic review initiatives, to be fully realized in 2026. The company plans to strengthen its scientific portfolio through strategic acquisitions, partnerships, and internal investments, while divesting certain underperforming or non-core assets representing approximately 7% of estimated 2025 revenue. It also intends to maintain a disciplined approach to capital deployment, balancing acquisitions, stock repurchases, and debt repayment. The company supports the FDA's initiatives to reduce animal testing and is committed to collaborating with regulatory agencies and the biopharmaceutical industry to develop and implement new, non-animal based technologies.

Management Comments

• "We are continuing to see a cautious spending environment from our client base, principally within our DSA segment related to our global biopharmaceutical and biotechnology clients, as they reassess their budgets, reprioritize their drug pipelines, and manage their cost structures."
• "We expect that these effectuated actions, as well as other upcoming planned actions designed to optimize our global footprint to drive greater operating efficiency, will result in approximately $225 million of cost savings on an annualized basis, of which approximately $175 million will impact fiscal year 2025."
• "We will focus on strategic initiatives to strengthen our leading scientific portfolio within our core markets through strategic acquisitions, partnerships, and internal investments; divest certain underperforming or non-core assets, which represent approximately 7% of the Company’s estimated 2025 revenue; maximize our financial performance, including by implementing additional initiatives aimed at driving greater operating efficiency, which are expected to generate incremental net cost savings of approximately $70 million annually, which will be fully realized in 2026; and maintain a disciplined approach to capital deployment through regularly evaluating the optimal balance between strategic acquisitions, stock repurchases, debt repayment, and other uses of capital."
• "We support the FDA’s announcement as we believe the program aligns with the vision previously outlined in the FDA Modernization Act 2.0 and aims to develop a clearer regulatory pathway to streamline the drug development process and safely advance innovative technologies, including alternatives to the current animal based development process."
• "We remain committed to continuing to collaborate with regulatory agencies, including the FDA, the biopharmaceutical industry and other stakeholders, to help develop, validate, and implement an efficient process for our clients regulatory submissions that support the use of new, non-animal based technologies."

Industry Context

The biopharmaceutical and biotechnology industries are currently characterized by a cautious spending environment, leading clients to re-evaluate budgets and drug pipelines. This trend is impacting demand for drug discovery and development services. Concurrently, there is a significant industry shift towards reducing animal testing in preclinical safety studies, driven by regulatory bodies like the FDA and advancements in New Approach Methodologies (NAMs) such as organ-on-a-chip systems and computational modeling. Global trade policies, including new tariffs imposed by the U.S. on various countries, are also influencing supply chains and operational costs for companies operating internationally.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• An ongoing inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) initiated on May 16, 2023, requesting information related to the sourcing of non-human primates and related disclosures. The company is cooperating, but the timing, outcome, and potential impact (fines, penalties, liabilities) are unpredictable.
• A putative securities class action lawsuit filed on May 19, 2023, against the company and certain current/former officers (James Foster, David R. Smith), alleging materially false or misleading disclosures regarding NHP importation. The U.S. Court of Appeals for the First Circuit reversed in part the district court's dismissal on August 15, 2025, returning the case to the U.S. District Court for the District of Massachusetts. A motion to substitute lead plaintiff was filed on October 16, 2025. The company believes the lawsuit is without merit and plans to vigorously defend against it.
• A stockholder derivative lawsuit filed on November 8, 2023, in the U.S. District Court of Delaware against Board members and certain current/former officers (James Foster, David R. Smith, Flavia Pease), alleging breaches of fiduciary duties related to NHP disclosures, internal controls, and compliance with the Code of Business Conduct and Ethics. This lawsuit is currently stayed.
• A second stockholder derivative lawsuit filed on August 2, 2024, in the U.S. District Court of Delaware against current and former Board members and the same current/former officers, asserting similar allegations plus insider-trading claims. This lawsuit is also currently stayed.
• Investigations by the U.S. Department of Justice (DOJ) and the U.S. Fish and Wildlife Service (USFWS) into NHP shipments from Cambodia (initiated February 17, 2023) were closed in the third fiscal quarter of 2025, and the NHP shipments were cleared for legal entry into the United States.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Impacted by decreased net income and EPS, ongoing litigation, and potential volatility from the strategic review. Potential benefits from stock repurchases and future cost savings are anticipated.
• Employees: Affected by workforce right-sizing actions and restructuring initiatives, which have resulted in severance and transition costs.
• Customers: Experiencing a cautious spending environment, leading to budget reassessments and reprioritization of drug pipelines. The company aims to enhance customer productivity and speed to market through its services and new methodologies.
• Suppliers: Potentially impacted by U.S. tariffs on imports from certain countries (e.g., Vietnam, Mauritius, China), which could affect costs and supply chain operations.
• Regulatory Authorities: The company is cooperating with the SEC inquiry and actively collaborating with the FDA on developing and implementing alternative testing methods, indicating a responsive stance to regulatory evolution.

Next Steps

• Continue to implement restructuring actions to optimize the global footprint and drive greater operating efficiency, aiming for approximately $225 million in annualized cost savings.
• Execute strategic initiatives to strengthen the leading scientific portfolio within core markets through strategic acquisitions, partnerships, and internal investments.
• Divest certain underperforming or non-core assets, which represent approximately 7% of the company's estimated 2025 revenue.
• Implement additional initiatives aimed at driving greater operating efficiency, expected to generate incremental net cost savings of approximately $70 million annually, fully realized in 2026.
• Maintain a disciplined approach to capital deployment through regularly evaluating the optimal balance between strategic acquisitions, stock repurchases, debt repayment, and other uses of capital.
• Vigorously defend against the putative securities class action lawsuit and the two derivative lawsuits.
• Continue to cooperate with the SEC inquiry related to NHP sourcing and disclosures.
• Collaborate with regulatory agencies, including the FDA, the biopharmaceutical industry, and other stakeholders, to help develop, validate, and implement efficient processes for clients' regulatory submissions that support the use of new, non-animal based technologies.

Key Dates

Recommendation

The company is navigating a challenging period marked by declining net income and EPS, a cautious client spending environment, and significant ongoing legal proceedings. While management has initiated a comprehensive strategic review, including restructuring for cost savings and a new stock repurchase program, the immediate financial performance is weak, and the outcomes of the legal matters remain uncertain. The strategic focus on core markets and alternative methodologies (NAMs) offers long-term potential, but the short-to-medium term outlook is clouded by these headwinds. Investors should hold their positions to observe the successful execution of the strategic review and the resolution of legal and regulatory issues before considering further investment actions.

Keywords

Charles River Laboratories, CRL, SEC filing, 10-Q, financial results, drug discovery, safety assessment, research models, manufacturing solutions, biopharmaceutical, biotechnology, NHP supply chain, SEC investigation, litigation, stock repurchase, strategic review, cost savings, FDA Modernization Act 2.0, NAMs, tariffs, operating income, net income, EPS, revenue